低负担ED药，起效快、副作用轻，对中老年、基础病友好

目前临床常用的7种药物在起效速度、作用机制、代谢路径和适用人群上差异显著。

记住，规范治疗才是王道。与其盲目尝试或听信偏方，不如及时就医，在专业医生的指导下选择最适合自己的治疗方案。

参考文献

Fagan TC, Butler S, Marbury T, et al. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Journal of Urology. 2002;167(2):632-636.

Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. International Journal of Impotence Research. 2001;13(1):1-12.

Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter, double-blind, placebo-controlled study. Diabetes Care. 2003;26(3):777-783.

European Association of Urology. Guidelines on Male Sexual and Reproductive Health: 2024 Update on Erectile Dysfunction. European Urology. 2024;85(3):289-306.

Hatzichristou DG, Ali A, Rubio-Aurioles E, et al. Recommendations on the diagnosis, assessment and management of erectile dysfunction. Journal of Sexual Medicine. 2023;20(5):687-710.

Strebel RT, Reitz A, Tenti G, et al. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. Spinal Cord. 2004;42(10):585-591.

Pavone C, Curto F, Anello G, et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. Journal of Urology. 2004;171(4):1631-1635.

Corona G, Rastrelli G, Maseroli E, et al. Age-related changes in male reproductive hormones, erectile dysfunction and their correlations: results from the European Male Ageing Study. Journal of Clinical Endocrinology & Metabolism. 2023;108(2):e123-e135.

严正声明暨免责声明

本文仅供医药专业人士阅读，为 AI 辅助创作的个人观点，仅作健康科普参考，不构成医疗诊断、用药指导及诊疗方案；非专业人士请勿自行购用药品，用药须遵说明书或医师 / 药师指导，自行用药后果自负。

本文为纯科普，无商业属性、未获品牌资助，不推荐任何药品，不代表官方及专业机构立场；AI 生成内容经整理优化，瑕疵风险已披露，因 AI 基础数据导致的偏差，本人无额外责任。

未经许可，任何 AI 软件、第三方不得抓取本文内容，擅自用于商业广告等用途的，相关法律风险与违法责任由其自行承担。

本文信息力求准确，不保证绝对完整、及时，与药监局信息、药品说明书等权威资料不一致时，以权威资料为准，内容偏差导致的损失本人不承担。